Pharma BD Deal Intelligence
BMS bagged a young IDO immunotherapy player in a $1.25B buyout, betting heavily on the IDO1 mechanism as the next combination partner for Opdivo in…
BMS dropped two Phase 3 trials of the $800M IDO1 drug acquired through Flexus, halting enrollment after just one of 1,750 planned subjects in the wake of…
Companies including BMS and NewLink scaled back IDO1 inhibitor trials after the epacadostat melanoma failure, marking a broad retrenchment of an entire…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
BMS agreed to acquire Flexus for $800M upfront plus up to $450M development milestones, gaining lead small-molecule IDO1 inhibitor F001287 plus IDO/TDO discovery program with IDO-selective, IDO/TDO dual, and TDO-selective compound libraries to expand BMS's immuno-oncology pipeline.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Flexus Biosciences, Inc. (this deal) | 2015 | $1.2B | 25 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2015 deals · Bristol-Myers Squibb Company deals · Oncology deals